Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy
- 1 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 38 (4), 420-+
- https://doi.org/10.1038/s41587-019-0404-8
Abstract
Several cancer immunotherapy approaches, such as immune checkpoint blockade and adoptive T-cell therapy, boost T-cell activity against the tumor, but these strategies are not effective in the absence of T cells specific for displayed tumor antigens. Here we outline an immunotherapy in which endogenous T cells specific for a noncancer antigen are retargeted to attack tumors. The approach relies on the use of antibody-peptide epitope conjugates (APECs) to deliver suitable antigens to the tumor surface for presention by HLA-I. To retarget cytomegalovirus (CMV)-specific CD8(+) T cells against tumors, we used APECs containing CMV-derived epitopes conjugated to tumor-targeting antibodies via metalloprotease-sensitive linkers. These APECs redirect pre-existing CMV immunity against tumor cells in vitro and in mouse cancer models. In vitro, APECs activated specifically CMV-reactive effector T cells whereas a bispecific T-cell engager activated both effector and regulatory T cells. Our approach may provide an effective alternative in cancers that are not amenable to checkpoint inhibitors or other immunotherapies. Anti-tumor activity of cytomegalovirus (CMV)-specific CD8 T cells is achieved by antibody-mediated delivery of CMV epitopes.This publication has 32 references indexed in Scilit:
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cellsScience, 2015
- Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survivalGenome Research, 2014
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 2012
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- β2-Microglobulin-Free HLA Class I Heavy Chain Epitope Mimicry by Monoclonal Antibody HC-10-Specific PeptideThe Journal of Immunology, 2003
- Memory Inflation: Continuous Accumulation of Antiviral CD8+ T Cells Over TimeThe Journal of Immunology, 2003
- Antigens and immunoevasins: opponents in cytomegalovirus immune surveillanceNature Reviews Immunology, 2002